Vincristine for the treatment of Kasabach-Merritt syndrome: recent New Zealand case experience

Presents a case series showing efficacious use of vincristine in treating Kasabach-Merritt syndrome (KMS), via a review of case notes of four children treated for KMS by the authors with corticosteroids and vincristine and with specific attention paid to the efficacy and adverse effects of each therapeutic agent. Suggests that vincristine should be considered a first-line agent, and that the use of systemic corticosteroids should not be routine. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.